Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [619]

ASCO 2022: Latest developments in mHSPC and mCRPC

Prof Heather Payne, Prof Kim Chi, Prof Laura-Maria Krabbe and Prof Kurt Miller

ASCO 2022: Latest developments in mHSPC and mCRPC ( Prof Heather Payne, Prof Kim Chi, Prof Laura-Maria Krabbe and Prof Kurt Miller )

COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity...

Dr Sumanta K. Pal - City of Hope Comprehensive Cancer Center, Duarte, USA

COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity in inoperable locally advanced/metastatic urothelial carcinoma ( Dr Sumanta K. Pal - City of Hope Comprehensive Cancer Center, Duarte, USA )

Safety follow-up of the randomized, phase 3 study DESTINY-Breast03

Dr Erika Hamilton - Sarah Cannon Research Institute, Tennessee, USA

Safety follow-up of the randomized, phase 3 study DESTINY-Breast03 ( Dr Erika Hamilton - Sarah Cannon Research Institute, Tennessee, USA )

Review: Best options in localised prostate cancer

Prof Eleni Efstathiou, Prof Oliver Sartor, Prof Kurt Miller and Prof Karim...

Review: Best options in localised prostate cancer ( Prof Eleni Efstathiou, Prof Oliver Sartor, Prof Kurt Miller and Prof Karim Fizazi )

Sacituzumab govitecan increases PFS for HR+/HER2- metastatic breast cancer

Dr Hope Rugo - University of California San Francisco, San Francisco, USA

Sacituzumab govitecan increases PFS for HR+/HER2- metastatic breast cancer ( Dr Hope Rugo - University of California San Francisco, San Francisco, USA )

ASCO GU 2022: Latest in mHSPC

Prof Eleni Efstathiou, Prof Karim Fizazi, Prof Kim Chi and Prof Matthew Smith

ASCO GU 2022: Latest in mHSPC ( Prof Eleni Efstathiou, Prof Karim Fizazi, Prof Kim Chi and Prof Matthew Smith )

An AI-derived digital pathology-based biomarker to predict the benefit of ADT...

Prof Daniel Spratt - University Hospitals Seidman Cancer Center, Cleveland, USA

An AI-derived digital pathology-based biomarker to predict the benefit of ADT in PC with validation in NRG/RTOG 9408 ( Prof Daniel Spratt - University Hospitals Seidman Cancer Center, Cleveland, USA )

The optimal approach after neoadjuvant treatment: The Lucerne toolbox

Prof Maria Cardoso - Champalimaud Foundation, Lisbon, Portugal

The optimal approach after neoadjuvant treatment: The Lucerne toolbox ( Prof Maria Cardoso - Champalimaud Foundation, Lisbon, Portugal )

OncoAlert Colloquium Day 6: Gynaecological oncology, IGCS and ESO

Dr Don Dizon, Dr Allison Betof Warner, Dr Giancarlo Pruneri, Dr Pierfrancesco...

OncoAlert Colloquium Day 6: Gynaecological oncology, IGCS and ESO ( Dr Don Dizon, Dr Allison Betof Warner, Dr Giancarlo Pruneri, Dr Pierfrancesco Franco & Dr Kathleen Schemeler )

OncoAlert Colloquium Day 5: SWOG, OncoAlliance and more

Dr John Haanen, Dr Vivek Subbiah, Dr Christian Rolfo, Dr Jessica Hwang, Dr...

OncoAlert Colloquium Day 5: SWOG, OncoAlliance and more ( Dr John Haanen, Dr Vivek Subbiah, Dr Christian Rolfo, Dr Jessica Hwang, Dr Nagla Karim, Dr Fumiko Chino, Dr Narjust Duma & Dr Nicole Kuderer )

OncoAlert Colloquium Day 4: GI oncology and EONS

Dr Cathy Eng, Dr Yelena Janjigian, Ms Stacy Hurt, Ms Allison Rosen, Dr Mark...

OncoAlert Colloquium Day 4: GI oncology and EONS ( Dr Cathy Eng, Dr Yelena Janjigian, Ms Stacy Hurt, Ms Allison Rosen, Dr Mark Lewis, Dr Nina Niu Sanford, Mr Johan de Munter & Dr Merel Van Klinken )

OncoAlert Colloquium Day 3: Breast cancer

Dr Erika Hamilton, Dr Bhawna Sirohi, Ms Ginny Mason RN, Dr Hope Rugo, Dr Sara...

OncoAlert Colloquium Day 3: Breast cancer ( Dr Erika Hamilton, Dr Bhawna Sirohi, Ms Ginny Mason RN, Dr Hope Rugo, Dr Sara Tolaney, Dr Matteo Lambertini & Dr Icro Meattini )

More from ecancer